These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9861230)

  • 1. MD reviewers' role in the new anticancer drug approval process in the newly established Japanese regulatory agency, PMDEC (Pharmaceuticals and Medical Devices Evaluation Center).
    Fujiwara Y
    Jpn J Clin Oncol; 1998 Nov; 28(11):653-6. PubMed ID: 9861230
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC).
    Fujiwara Y; Kobayashi K
    Crit Rev Oncol Hematol; 2002 May; 42(2):145-55. PubMed ID: 12007972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Review process of new oncology drug application in Japan--role of MD reviewer].
    Fujiwara Y
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):196-203. PubMed ID: 9987519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of the last 15 years: from PMDEC to PMDA --looking back at the first stage of the PMDEC].
    Morimoto K; Fujiwara Y; Kawahara A
    Yakushigaku Zasshi; 2011; 46(1):38-50. PubMed ID: 22164689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
    Maruyama H; Kondo T
    Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.
    Sato M; Ochiai Y; Kijima S; Nagai N; Ando Y; Shikano M; Nomura Y
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):413-415. PubMed ID: 28568566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current PMDA Activities for Use of Biomarkers in Drug Evaluation].
    Ishiguro A
    Yakugaku Zasshi; 2015; 135(5):681-4. PubMed ID: 25948301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].
    Masuyama K
    Yakugaku Zasshi; 2013; 133(2):183-6. PubMed ID: 23370511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug evaluation and approval in the European Community.
    Marty M
    Eur J Cancer; 1996 Apr; 32A(4):574-5. PubMed ID: 8695255
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery and development of molecularly targeted drugs: regulatory perspectives.
    De Andres-Trelles F
    J Chemother; 2004 Nov; 16 Suppl 4():19-21. PubMed ID: 15688603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Pharmaceuticals and Medical Devices Agency's Approach to Facilitate Risk Communication and Its Challenges].
    Kondo E; Torii M; Oba I; Okamoto M
    Yakugaku Zasshi; 2018; 138(3):307-314. PubMed ID: 29503421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PMDA's challenge to accelerate clinical development and review of new drugs in Japan.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Oct; 88(4):454-7. PubMed ID: 20856242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug approval process in Japan.
    Hayakawa T
    Curr Opin Biotechnol; 1999 Jun; 10(3):307-11. PubMed ID: 10361082
    [No Abstract]   [Full Text] [Related]  

  • 15. [Development of an anticancer drug in Japan based on a new clinical trial system].
    Nakashima H; Nakano S
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Activities and future directions of PMDA (Pharmaceuticals and Medical Devices Agency)].
    Kondo T
    Nihon Yakurigaku Zasshi; 2012 May; 139(5):211-4. PubMed ID: 22687874
    [No Abstract]   [Full Text] [Related]  

  • 18. PMDA's Vision for Horizon Scanning of Emerging Technologies Potentially Relevant to the Development of New Medical Products: The Regulatory Challenge.
    Shimokawa M; Sato D; Wakao R; Arai H
    Clin Pharmacol Ther; 2021 Feb; 109(2):295-298. PubMed ID: 33469964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 20. [Doctor-initiated clinical trials and the revised pharmaceutical affairs law].
    Takano T; Saijo N
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1391-7. PubMed ID: 14584270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.